Olivier Didur is an experienced toxicologist with more than 10 years of experience at CROs, in preclinical research and development for pharmaceutical products, and in IND-enabling programs. He has performed more than 100 studies, including first compound administration for maximum tolerated dose determination, long-term administration, and DART studies.

He also has experience with multiple routes of administration, such as inhalation/intranasal, intravenous, intradermal, subcutaneous, and oral routes. He has expertise in designing and interpreting toxicology, safety pharmacology, inhalation, and toxicokinetic studies, per ICH and GLP guidelines, and a proven ability to manage studies, timelines, budgets, and multisite programs.

With deep knowledge of the scientific, technical, and regulatory aspects of toxicology and safety pharmacology, Olivier is well–versed in:

1. Planning, coordinating, and supervising preclinical toxicology studies in drug discovery projects according to OECD and FDA guidelines
2. Managing preclinical safety trials – designing and monitoring studies, discussing findings, and reporting
3. Industrial research workflows and regulatory assessments
4. Regulatory (ICH, EMA, and OECD) and GLP quality standards for preclinical pharmaceutical products